Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1595-1599

  Romero Aroca, Pedro ^a   Sararols, Laura ^b   Arias, Lluis ^c   Casaroli Marano, Ricardo P ^d   Bassaganyas, Francisca ^e  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Antibiotics; Azithromycin; Endophthalmitis prophylaxis; Intravitreal injections; Ofloxacin

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BEVACIZUMAB; OFLOXACIN; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PUNCTATE KERATITIS; SIDE EFFECT; SPAIN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SUBCONJUNCTIVAL HEMORRHAGE; UVEITIS; VISUAL ACUITY; VITRECTOMY;

EID: 84867559555     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S35795     Document Type: Article

References (34)

1. Prasad AG, Schaudlu R, Apte RS. Intravitreal pharmacotherapy: applications in retinal disease. Compr Ophthalmol Update. 2007;8(5): 259-269.
2. Irigoyen C, Ziahosseini K, Morphis G, Stappler T, Heimann H. Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol. 2012;250(4):499-505.
3. Bodaghi B, Korobelnik JF, Cochereau I, Hajjar J, Goebel F, Dumarcet N; AFSSAPS (Association Francaise de Securite Sanitaire des Produits de Sante). Intravitreal injections: AFSSAPS guide to good practice. J Fr Ophtalmol. 2012;35(1):69-71. French.
4. Waisbourd M, Goldstein M, Loewenstein A. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel. Isr Med Assoc J. 2011;13(3):141-146.
5. Simunovic MP, Rush RB, Hunyor AP, Chang AA. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol. 2012;96(6):862-866.
6. Bhavsar AR, Stockdale CR, Ferris FL, Brucker AJ, Bressler NM, Glassman AR; Diabetic Retinopathy Clinical Research Network FT. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol. 2012;130(6):809-810.
7. Angulo Bocco MC, Glacet-Bernard A, Zourdani A, Coscas G, Soubrane G. Intravitreous injection: retrospective study on 2028injections and their side effects. J Fr Ophtalmol. 2008;31(7):693-698. French.
8. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609-1614.
9. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, etal. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31(4): 662-668.
10. Jensen MK, Fiscella RG, Moshirfar M, Mooney B. Third-and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years. J Cataract Refract Surg. 2008;34(9):1460-1467.
11. O'Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg. 2007;33(10):1790-1800.
12. Wejde G, Montan P, Lundström M, Stenevi U, Thorburn W. Endophthalmitis following cataract surgery in Sweden: national prospective survey 1999-2001. Acta Ophthalmol Scand. 2005;83(1): 7-10.
13. Seal DV, Barry P, Gettinby G, etal. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: case for a European multicenter study. J Cataract Refract Surg. 2006;32(3):396-406.
14. Garat M, Moser CL, Martín-Baranera M, Alonso-Tarrés C, Alvarez-Rubio L. Prophylactic intracameral cefazolin after cataract surgery: endophthalmitis risk reduction and safety results in a 6-year study. J Cataract Refract Surg. 2009;35(4):637-642.
15. Romero P, Méndez I, Salvat M, Fernández J, Almena M. Intracameral cefazolin as prophylaxis against endophthalmitis in cataract surgery. J Cataract Refract Surg. 2006;32(3):438-441.
16. Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27(1):10-12.
17. Bhavsar AR, Googe JM Jr, Stockdale CR, etal. Risk of endophthalmitis after intravitreal injection when topical antibiotics are not required. Arch Ophthalmol. 2009;127(12):1581-1583.
18. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676-698.
19. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113(12):1479-1496.
20. Barry P, Gardner S, Seal D, etal. Clinical observations associated with proven and unproven cases in the ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. J Cataract Refract Surg. 2009;35(9):1523-1531.
21. Baquero F, Martínez-Beltrán J, Cantón R. Criteria of the MENSURA group for the definition of the critical points of sensitivity to antibiotics. Enferm Infecc Microbiol Clin. 1998;16(2):85-92. Spanish.
22. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard. NCCLS document M2-A7. 7th ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
23. Mitchell P, Bandello F, Schmidt-Erfurth U, etal. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
24. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007;144(3):454-456.
25. Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002;133(4):484-498.
26. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654-661.
27. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina. 2011;31(10):2032-2036.
28. Royal College of Ophthalmologists. Guidelines for Intravitreal Injections Procedure. London, UK: Royal College of Ophthalmologists, 2009. Available from: http://www.rcophth.ac.uk. Accessed August 28, 2012.
29. Sociedad Española de Retina y Vítreo. Manejo de las inyecciones intravítreas. [Management of intravitreal injections]. Guías de Práctica Clínica de la SERV. 2009. Available from: http://www.serv.es. Accessed August 28, 2012. Spanish.
30. Agence Français de Sécurité Sanitaire des Produits de Santé. Bonnes pratiques d'injection intra-vitréenn. [Good practice for intravitreal injection]. 2011. Available from: http://www.ansm.fr. Accessed August 28, 2012. French.
31. Retsema J, Girard A, Schelkly W, etal. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother. 1987;31(12):1939-1947.
32. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992;44(5):750-799.
33. Chiambaretta F, Garraffo R, Elena PP, etal. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eye drops (T1225) in healthy volunteers. Eur J Ophthalmol. 2008;18(1):13-20.
34. Cochereau I, Meddeb-Ouertani A, Khairallah M, etal. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol. 2007;91(4):465-469.